76. Advancing immuno-oncology, Michel Detheux, President and CEO, iTeos Therapeutics
Michel Detheux is the co-founder, President, and CEO of iTeos Therapeutics, and has held the role of CEO since the company’s inception in 2012. He previously served as a director at Ludwig Cancer Rese...
20 Loka 202121min
75. Innovations in cell therapies via microfluidics, Armon Sharei, CEO and Founder, SQZ Biotech
Armon Sharei, PhD, is the Chief Executive Officer and Founder of SQZ Biotechnologies, a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients arou...
13 Loka 202130min
74. Pioneering circular oRNA therapeutics, Thomas Barnes, Chief Executive Officer, Orna Therapeutics
Thomas is a veteran entrepreneur who has turned creative scientific visions into successful businesses for both startups and established organizations for over 20 years and has co-founded or helped la...
6 Loka 202124min
73. Patient focused gene editing for heart disease, Andrew Bellinger, CSO/CMO, Verve Therapeutics
Andrew Bellinger is chief scientific officer of Verve Therapeutics. He is a general cardiologist at Brigham and Women’s Hospital and is board-certified in cardiovascular medicine and internal medicine...
29 Syys 202122min
72. Unlocking biologic drug production, Brian Finrow, Co-Founder and CEO, Lumen Bioscience
Brian Finrow brings the skills and experience of a lawyer to a position that, in the biotech world, is more typically occupied by a scientist. This is essential to an enterprise like Lumen, which is r...
22 Syys 202120min
71. Leadership in immuno-oncology, Jeffrey Goldberg, President and CEO, Immunitas Therapeutics
Jeffrey Goldberg is the president and CEO of Immunitas. Jeff is an experienced biotech program and brand leader with over 20 years of industry experience. He has driven programs from discovery and pre...
15 Syys 202121min
70. Modern treatments for psoriasis and atopic dermatitis, Todd Zavodnick, CEO, Dermavant Sciences
Todd Zavodnick has over 20 years of leadership experience in the biopharmaceutical industry. Prior to joining Dermavant in November 2018, Mr. Zavodnick served as Chief Commercial Officer and President...
25 Elo 202128min
69. Antibodies in immuno-oncology, Alison O'Neill, Chief Medical Officer, Surface Oncology
Alison serves as the chief medical officer at Surface Oncology. She has over 20 years of experience in clinical research, oncology drug development and clinical neuro-oncology. Prior to joining Surfac...
18 Elo 202119min
